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The number of diabetic patients in Europe and world-wide is growing. Diabetes
confers a 2-fold higher risk for vascular disease. Lack of insulin production (Type
1 diabetes, T1D) or lack of insulin responsiveness (Type 2 diabetes, T2D) causes
systemic metabolic changes such as hyperglycemia (HG) which contribute to the
pathology of diabetes. Monocytes and macrophages are key innate immune cells
that control inflammatory reactions associated with diabetic vascular complications.
Inflammatory programming of macrophages is regulated and maintained by epigenetic
mechanisms, in particular histone modifications. The aim of our study was to identify
the epigenetic mechanisms involved in the hyperglycemia-mediated macrophage
activation. Using Affymetrix microarray profiling and RT-qPCR we identified that
hyperglycemia increased the expression of S100A9 and S100A12 in primary human
macrophages. Expression of S100A12 was sustained after glucose levels were
normalized. Glucose augmented the response of macrophages to Toll-like receptor
(TLR)-ligands Palmatic acid (PA) and Lipopolysaccharide (LPS) i.e., pro-inflammatory
stimulation. The abundance of activating histone Histone 3 Lysine 4 methylation
marks (H3K4me1, H3K4me3) and general acetylation on histone 3 (AceH3) with
the promoters of these genes was analyzed by chromatin immunoprecipitation.
Hyperglycemia increased acetylation of histones bound to the promoters of S100A9
and S100A12 in M1 macrophages. In contrast, hyperglycemia caused a reduction in
total H3 which correlated with the increased expression of both S100 genes. The
inhibition of histone methyltransferases SET domain-containing protein (SET)7/9 and
SET and MYND domain-containing protein (SMYD)3 showed that these specifically
regulated S100A12 expression. We conclude that hyperglycemia upregulates expression
of S100A9, S100A12 via epigenetic regulation and induces an activating histone
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code on the respective gene promoters in M1 macrophages. Mechanistically, this
regulation relies on action of histone methyltransferases SMYD3 and SET7/9. The results
define an important role for epigenetic regulation in macrophage mediated inflammation
in diabetic conditions.
Keywords: diabetes mellitus, inflammation, macrophage, epigenetic, histone code, metabolic memory
INTRODUCTION
Diabetes confers an about 2-fold higher risk for cardiovascular
disease (1, 2). Type 1 diabetes (T1D) is an autoimmune
disease in which the immune system destroys pancreatic beta
cells and renders patients dependent on insulin administration.
Type 2 diabetes (T2D) is associated with insulin resistance
i.e., the inability of tissue cells to respond to insulin. Obesity
is a strong predictor for T2D, while T2D itself increases
risks for cardiovascular disease and cancer. Both in T1D
and T2D the chronic exposure to increased glucose serum
levels (hyperglycemia) causes pathophysiological changes that
are largely of an inflammatory nature (3, 4). Macrophages
are important in homeostasis of metabolism of tissues as
well as whole body metabolism whereas on the other side,
the intrinsic metabolism of the cell shapes its activation
state (5, 6). Macrophages respond to their environment
with either pro-inflammatory (M1) or anti-inflammatory (M2)
fashion and can be polarized in both directions, defined
Abbreviations: 18S rRNA, 18S ribosomal RNA; AGEs, Advance glycation
endproducts; ATP, Adenosine triphosphate; BHQ1, Black Hole Quencher-1;
BMDM, Bone-marrow-derived macrophage; CD, Cluster of differentiation;
ChIP, Chromatin immunoprecipitation; COPD, Chronic Obstructive
Pulmonary Disease; DCCT, Diabetes Control and Complications Trial;
DMSO, Dimethylsulfoxide; DNA, Deoxyribonucleic acid; DRAQ5, Deep
Red Anthraquinone 5; EC, endothelial cell; ECM, Extracellular Matrix
Metalloproteinase; EMMPRIN, Extracellular Matrix Metalloproteinase Inducer
(CD147); ERK1/2, Extracellular signal–regulated kinase; FACs, Fluorescence-
activated cell sorting; FAM, 6-carboxyfluorescein; FCS, Fetal Calf Serum;
FG, Fasting glucose; G6PD, glucose-6-phospate dehydrogenase; GAPDH,
Glyceraldehyde 3-phosphate dehydrogenase; GC, Guanine-cytosine nucleotides;
GLO1, Glyoxalase I; GLUT1, Glucose transporter 1; H3K4me, Histone 3 lysine 4
methylation; HAT, Histone acetyltransferases; HbA1c, Hemoglobine A1c; HDAC,
Histone deacetylase; HG, Hyperglycemia; HLA-DR, Human leukocyte antigen-
DR; HMGB1, High mobility group box1; HMT, Histone methyltransferases;
IFNγ, Interferon gamma; IgG, Immunoglobulin G; IL, Interleukin; JNK, c-Jun
N-terminal kinases; LPS, Lipopolysaccharide; MACS, Magnetic activated cell
sorting; MAPK, Mitogen-activated protein kinase; MC, Mesangial cell; MCSF,
Macrophage colony-stimulating factor; MLL, Mixed Lineage Leukemia; MMP,
Matrix Metalloproteinase; mTOR, Mammalian target of rapamycin; NADH,
Nicotinamide-adenine-dinucleotide hydride; NF-κB, Nuclear factor kappa-
light-chain-enhancer of activated B cells; NO, Nitric oxide; PA, Palmatic Acid;
PBMC, Peripheral blood mononuclear cell; PBS, Phosphate buffered saline; PFA,
Paraformaldehyde; PPP, Pentose-phosphate pathway; PRDM, PRDI-BF1 and
RIZ homology domain containing; RAGE, Receptor for AGE; RNA, Ribonucleic
acid; ROS, Rective oxygen species; RPMI, Roswell Park Memorial Institute; RT,
Room temperature; RT-qPCR, Quantitative reverse transcription PCR; SET7/9,
SET domain-containing protein 7; SFM, Serum-Free Media; SMYD3, SET and
MYND domain-containing protein 3; SOD2, Superoxide dismutase 2; SWI/SNF,
SWItch/Sucrose Non-Fermentable; T1D, Type 1 diabetes; T2D, Type 2 diabetes;
TF, Transcription factor; TLR, Toll like receptor; TSS, Transcription start site;
UCP1, Mitochondrial uncoupling protein 1; VSMC, vascular smooth muscle cell;
WDR5, WD Repeat Domain 5.
as “macrophage plasticity.” In diabetic retinopathy activated
resident macrophages i.e., microglia, produce inflammatory,
and neurotoxic mediators that that disrupt vascular integrity
and function (7). Macrophage recruitment and activation
contribute to diabetic nephropathy (8) and diabetic neuropathy
(9). The inability to switch phenotype from pro-inflammatory
to anti-inflammatory macrophages, has been hypothesized to
mediate delayed wound healing seen in diabetic patients (10).
Metabolic memory referes to the beneficial effects i.e., reduced
incidence and progression of diabetic complications, of intensive
glycemic control seen after return to normal therapy during
the Diabetes Control and Complications Trial (DCCT) (11).
Post-prandial hyperglycemia and spikes in glucose levels may
not reflect fasting plasma glucose and the commonly used
serum marker for diabetes Hemoglobine A1c (HbA1c) (12,
13). Therefore, transient periods of hyperglycemia can also
cause in diabetic patients cellular changes that do not alter
upon normalization of blood glucose levels (14, 15). Epigenetic
modifications have been postulated to confer hyperglycemic
memory in target cells involved in vascular dysfunction including
endothelial cells (ECs), vascular smooth muscle cells (VSMCs),
and renal mesangial cells (MCs) (16). Chemical modifications
at histone tails that surround gene promotors can inhibit
or stimulate gene expression. Most-studied modifications are
methylation and acetylation on Histone 3 (H3) that mainly occur
on the side chains of lysines (K) and arginines residues (17).
Since S100 genes do not contain CpG islands, and were
not identified in methylation screening assays on diabetic
samples, we decided to focus on histone modifications
which generally preceed DNA methylation in epigenetic
reprogramming. Histone code also is essential for macrophage
programming in inflammatory conditions related to infections
(18, 19). Monocytes can respond in different ways upon
restimulation. Chromatin modifications discriminate opposing
functional programs for either enhanced (training) or decreased
(tolerance) cytokine production, depending on the type of stimuli
encountered (20–22). In a diabetic (micro)environment, glucose
and its byproducts i.e., Advance glycation endproducts (AGEs)
cause epigenetic changes in the bone marrow. This causes
a diabetic preconditioning of monocytes and macrophages
(23, 24). Blood monocytes of diabetic patients who had joined
the DCCT showed increased H3K9Ac on gene promoters related
to NF-κB inflammatory pathways. High H3K9ac levels correlated
with HbA1c and progression of retinopathy or nephropathy
after 10 year of follow-up in patients with type 1 diabetes
(25). Also, several histone modification on the promoters
and enhancers of inflammatory regulators in macrophages
are related to the progression of atherosclerosis (26). Histone
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modifications are written and removed by histone modifying
enzymes. Histone methyltransferases responsible for H3K4me
are the histone methyltransferase Mixed Lineage Leukemia
(MLL) family, SET1A, SET1B, SET7/9, SMYD, and PRDI-BF1
and RIZ homology domain containing (PRDM)9. Differences are
that SET7 exhibits monomethylation activity whereas SMYD3,
MLL1/2, and MLL3/4 trimethylate H3K4 (27). SET7 has been
shown to be sensor for hyperglycemic changes in EC (28)
whereas MLL has been found to be important in macrophages
differentiation (29, 30).
Recenlty we have performed a systematic analysis of the effect
of hyperglycemia on the trascriptional program of differentially
activated human primary macrophage subtypes. We showed
that hyperglycemia upregulates expression of several members
of the S100 protein family. The highest effect of hyperglycemia
was gene expression of S100A9 and S100A12, in particular
in pro-inflammatory M1 macrophages which are maturated
with MCSF and simultaneously stimulated with IFNγ, and
for S100A8 in M0 macrophages, maturated without additional
stimulation (Supplementary Table 1). The original array data
for all differentially activated genes is accessible at NCBI GEO
database accession GSE86298 and will be published elswhere.
Highest levels of S100A9 are expressed in neutrophils and
monocytes, while expression of S100A12 is more restricted to
neutrophils (31, 32). However, S100 proteins are also produced
and function in other cell types like keratinocytes, fibroblasts,
epithelial, and endothelial cells (33, 34). S100A9 and S100A12 are
produced during inflammatory conditions, and their biological
effects depend on different activation states of the producing
cells, concentration as well as the composition of the local
milieu (35). Both proteins activate cells via RAGE (36, 37)
and S100A9 activates TLR4 (38) but also regulates macrophage
function via CD68 (39). Macrophage migration is promoted
by S100A9 via Extracellular Matrix Metalloproteinase (ECM)
Inducer EMMPRIN (CD147) (40). S100A9 is regulated by
MMPs (41) but also blocks MMP degradation of the ECM
(42). S100A9 appears to control the oxidative potential of
the NADPH complex, S100A8/A9 binding to cell receptors
induces signal transduction through NF-κB pathways (40, 43,
44). Besides formation of homomultimers, S100A9 may dimerize
with S100A8, or form S100A8/A9 tetramers called calprotectin
(45). Pro-inflammatory activity of S100A9 can be restricted by
formation of the calcium-induced (S100A8/S100A9)2 tetramer
that can not bind TLR4/MD2, thus preventing undesirable
systemic inflammatory effects (46). Genome-wide transcriptional
profiling of nerve stumps in the sciatic nerve axotomy model
in rats identified that S100A8 and S100A9 are key factors that
initiate the early inflammatory program in injured peripheral
nerves (47). Ccalprotectin is an acute phase protein and
detects already minimal inflammation levels and is suggested as
biomarker in (chronic) inflammatory diseases (48, 49).
Expression levels of S100A8, S100A9 (50, 51) and circulating
levels (52, 53) of S100A12 (ENRAGE) and soluble receptor for
(R)AGE (54, 55) positively correlate with diabetes pathology.
Serum levels of S100A9 and calprotectin were higher in T1D
patients compared to healthy controls (56), and correlated with
the progression of diabetic retinoptahy in T2D patients (57), but
also with insulin resistance/type 2 diabetes, metabolic risk score,
and fat cell size caused by obesity (58). S100 proteins are major
RAGE ligands and inflammation through RAGE is thought to
be central target in diabetic complications as well as diabetes
induced cancer (59).
Thus, taking into account that S100 proteins are essential
regulators of inflammation and their elevated levels are associated
with diabetes, in this study we focused on the mechanism
of regulation of S100 gene expression under hyperglycemic
conditions in macrophages as key innate immune cells that
contribute to both inititation and progression of diabetes and
its complications. By analysis of S100 gene expression we tested
the hypothesis that hyperglycemia in diabetic patients induces
long-term activation through epigenetic mechanisms similar to
trained immunity (24, 60) in primary human macrophages.
MATERIALS AND METHODS
Peripheral Blood Mononuclear Cell (PBMC)
of Diabetic Patients
Frozen PBMC samples of diabetic patients seen at the University
Hospital Heidelberg, Germany were used in the study. All studies
were approved by the ethics and review committee of Medical
Faculty Heidelberg, University of Heidelberg (ethic-vote-number
S-383/2016; clinical trial number NCT03022721). For gene
expression analysis by RT-qPCR, PBMCs from healthy controls
(n = 21), Prediabetic individuals (n = 19), T1D (n = 19),
and T2D (n = 21) patients were obtained (clinical data are
presented in Supplementary Table 2). Pre-diabetes was defined
based on increased fasting glucose between 100 and 125 mg/dl
or an impaired glucose tolerance—with elevated blood glucose
levels between 140 and 199 mg/dl after intake of 75 g glucose.
Within the group of T1D patients 75% of the subjects suffered
from neuropathy, 37.5% from retinopathy and 17.6% from
nephropathy. Also, patients with the group with T2D diabetes
suffered from polyneuropathy (76.2%) and/or nephropathy
(52.4%) and showed albuminuria. For analysis by flow cytometry,
PBMCs from T2D patients with microvascular complications
(n = 11) compared to healthy controls (n = 4) were used of
which the clinical data are presented in Supplementary Table 4.
Samples were processed as descibed in detail below.
Monocyte Isolation and Generation of
Macrophages
Human monocytes were isolated from buffy coats from
individual donors as described (61) with modifications. Buffy
coats were provided by the German Red Cross Blood Service
Baden-Württemberg – Hessen. Buffy coats were obtained
from healthy donors after informed consent. Selection of
monocytes occurred through selection by anti-CD14 antibodies
and magnetic activated cell sorting (MACS) (Milteny Biotech,
US). The obtained monocytes were cultured at 1 × 106 cell/ml
in customized serum free medium (SFM) with 5mM (normal
glucose) and 25mM (high glucose) glucose (Life Technology,
Germany) at a concentration of 1 × 106 cells/ml, supplemented
with cytokines (see below) in the presence of 7.5% CO2 for
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the time periods up to 6 days without medium change. For
ChIP experiments 20 × 106 cells were seeded in 100mm
cell culture dish and for RNA-isolations 3 × 106 in 6-well-
plates without additional coatings. Cells were incubated with
cytokines derived from PeproTech (Germany) in the presence
of 7.5% CO2 for 6 days. 5 ng/ml Macrophage colony-stimulating
factor (MCSF) and 100 ng/ml interferon-gamma (IFNγ) was
used to induce M1 macrophage polarization and 5 ng/ml MCSF
with 10 ng/ml IL-4 to induce M2 macrophage polarization. M0
macrophages were but MCSF not additionally stimulated (ns).
For all reagents used, identifiers are listed in a Key Resource Table
(Supplementary Table 5).
RNA Isolation and cDNA Synthesis
Cells were lysed in TRK lysis buffer and RNA was isolated using
E.Z.N.A. Total RNA kit (Omega Bio-tek, USA) according to the
manufacturer’s instructions. The concentration of isolated RNA
was determined with a Tecan Infinite R© 200. cDNA synthesis
was performed using Fermentas RevertAid cDNA synthesis Kit
(Thermo Scientific, US) with oligo-dT primers according to the
manufacturer’s instructions. The obtained cDNAwas diluted 1:10
with double distilled water and 1 µl was used for PCR.
Flow Cytometry
Frozen PBMCs from diabetic patients and healthy controls,
were thawed and plated in RPMI medium supplemented with
10% fetal calf serum (FCS) and 1% penicillin, streptomycin
and 5mM of glucose. Cells were incubated overnight at 37◦C,
with the diabetic group consisting of patients with severe
complications, consisting of nephropathy and additional patients
with nephropathy and cardiovascular disease. The next day,
the cells were harvested and washed with Phosphate buffered
saline (PBS). Fixable viability dye (FVD, Thermofisher) was
added to all unstained, IgG control and stained Fluorescence-
activated cell sorting (FACs) tubes and incubated for 30min
at 4◦C protected from light. Cells were washed twice with
FACS Buffer (PBS, 0.4% BSA, 0.02% NaN3). Ten microliter
FcR Blocking Reagent (Miltenyi Biotec) was added to all tubes
and incubated for 5min at RT. Antibodies (Table 1) were
added to stained tube and incubated 20min at 4◦C in the
dark. Cells were washed twice with cellwash, resuspended cells
in PBS and fixed with 3.5% Formaldehyde while vortexing.
After 15min at RT in the dark, cells were washed with PBS
and resuspended in 0.1% Saponin (Roth) and left on ice for
15min. Cells were centrifuged, resuspended in 0.1% Saponin.
Ten microliter FcR block was added and incubated for 5min
on ice. For intracellular staining antibodies or isotype controls
for the critical colors were added to the respective tubes and
incubated for 30min on ice. Cells were washed twice with
0.1% Saponin, resuspended in FACS Buffer and analyzed by BD
FACS Canto II. Antibodies for the following markers were used:
Human leukocyte antigen-DR (HLA)-DR, CD3, CD19, CD56,
CD16, and CD14 (Biolegend). Names of antibody clones are
provided in the Key Resource Table (Supplementary Table 5).
Cells were selected that were positive for HLA-DR. Cells positive
for CD3, CD19, and CD56 were excluded. Using a scatter
plot of CD16 vs. CD14 monocyte population were separated
TABLE 1 | Antibodies used for flow cytometry.
Marker Conjugate Control
isotype-matched ab
Volume per assay (µl)
CD16 APC Na 2.5
CD3 FITC Na 1
CD19 FITC Na 1
CD56 FITC Na 1
CD14 PerCPCy5.5 Na 1
HLA-DR PE Cy7 Na 0.5
S100A9 PE IgG1, κ 0.5
S100A12 AF405 IgG2b 5
Na, not applicable.
TABLE 2 | Primers used for 18SRNA.
Gene Primer Sequence (written 5’-3’)
18S rRNA Forward CCATTCGAACGTCTGCCCTAT
18S rRNA Reverse TCACCCGTGGTCACCATG
18S rRNA Probe ACTTTCGATGGTAGTCGCCGTGCCT
into classical (CD14+CD16–), non-classical with low CD14
expression (CD14–CD16+) and intermediate (CD14+CD16+)
monocytes. These populations were analyzed for the expression
S100A9 and S100A12.
Gene Expression Analysis
Primers and probes were obtained from Eurofins (Germany).
Dual-labeled probes were used containing 6-carboxyfluorescein
(FAM) on the 5′ end and a Black Hole Quencher-1 (BHQ1)
at the 3′ end of the sequence. Primers for 18S ribosomal
RNA (18S rRNA) were designed (Table 2). Primer sequences
are shown from the 5′ end to 3′ end direction. Taqman ready
to use human primers for S100A9 (Hs00610058_m1), S100A12
(Hs00942835_g1) were obtained from Thermo Scientific (US).
For endogenous control 18S rRNA was used. Use of 18S
was validated compared to other housekeeping genes (data
not shown).
Chromatin Immunoprecipitation (ChIP)
ChIP was used to assess the relative abundance of activating
histone marks at the promoter regions of the genes of interest.
ChIP assays were performed with SimpleChIP R© Enzymatic
Chromatin IP Kit (Cell Signaling Technology, US) according
to the manufacturer’s protocol. To crosslink proteins to DNA,
formaldehyde was added to the medium to a final concentration
of 1% and incubated at RT for 10min. Glycine was added for
5min to neutralize unreacted formaldehyde. Media was removed
and cells were washed twice with ice-cold PBS scraped and
taken in 2ml PBS + 10 µl (200x) PIC buffer provided in the
kit. Cells were lysed and chromatin was digested within buffers
provided. Digestion was done by micrococcal nuclease (2,000
units/µl) with an optimized ratio of 0.5 µl per 5 × 106 cells
harvested at 37◦ for 20min. Chromatin was sonicated to obtain
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TABLE 3 | Primers used for ChIP on human S100A9 promoter.
Gene
promoter
Promoter region Primer Sequence 5’-3’
S100A9 F GCCTGGTGCTAAGACTTTGG
P1 −108 17 R GCATGACAATGAAGCAGGGT
Pr AGCAGGCAGCATCCCTGCCT
F TGAGCTCTTCCCAACTTTCCA
P2 −551 −420 R CTCACACTGCTGAGATGCAC
Pr ACTGCCTAAGGTCACACAGACAGTCTG
F GCATTACCACACTGCTCACC
P3 −1241 −1117 R GAGCCACACAGAGTGTTTGC
Pr TGGCCCTTTGGCCCTGTCTC
F TCCGGGTGTCAGTTTCTTCA
P4 −1715 −1544 R TGCCTGGCTCTGTGATACTTA
Pr TGCAAGAGGGTTGCCCACCTCT
F GCTGTGTGCATAGGAGAAGG
P5 −2722 −2546 R TCTGGCTCTCAACACTTGCT
Pr TGCCTCTGTCCAACAATTGGCTGTAGA
fragments of 150–900 base pairs. Digestion was analyzed by an
1% agarose gel. For immunoprecipitation digested chromatin
of 5 × 106 cells was diluted into ChIP buffer and and 2 µg
of primary antibody H3K4me1 (Abcam, UK) H3K4me3and
acetylated histone H3 (Merck Millipore, Germany) was used in
a final volume of 0.5ml and incubated at 4◦C with rotation
overnight. Normal rabbit immunoglobulin G (IgG) and total H3
(D2B12) wer used as controls for the IP. Immune complexes
were captured using 30 µl of ChIP Grade Protein G Magnetic
Beads provided. The chromatin was eluted in elution buffer
provided and crosslinks were reversed by adding 6 µl 5M
NaCl and 2 µl Proteinase K and incubation for 2 h at 65◦C.
The DNA was purified using QIAquick PCR Purification Kit
(Qiagen, Germany). The amount of precipitated genomic DNA
concentration wasmeasured with a Tecan Infinite R© 200. Samples
were subjected to RT-PCR using primers for different promoter
regions of S100A9, S100A12 (Tables 3, 4). Onemicroliter of DNA
was added to each well. PCR reactions included a 2% input
sample and a well with no DNA to control for contamination.
Signals obtained from each immunoprecipitation are expressed
as a percent of total input chromatin. IP efficiency was calculated
with the following equation: Percent Input = 2% x 2(CT
2%Input Sample – CT IP Sample). 3,000 bp upstream of the
transcription start site (TSS), defined by SwitchGear genomics
tool in the Epigenomebrowser.org, was used to scan for suitable
ChIP primers.
Viability Assay
Alamar blue solution (Life technologies, Germany) 10% was
added to the medium and the cells and the cells were
incubated in the presence of 7.5% CO2 at 37
◦C for 3 h.
Fluorescence wasmeasured in triplicates at 590 nm read by Tecan
Infinite R© 200. Fluorescence of pure AlamarBlue was used as a
negative control.
TABLE 4 | Primers used for ChIP on human S100A12 promoter.
Gene
promoter
Promoter region Primer Sequence 5’-3’
S10012 F ACAGCCTGAGTGTCTTGTTT
P1 −83 56 R ACTGATCCTCTGCTCCAGTG
Pr ACCTCCTCCTAAGTCGTTCTGGGATGC
F CCCACACCTGTGAAGATAAGC
P2 335 497 R CCCACCCAGGTTGGTTTCTA
Pr ACCAATCTCACAACTTGCCCACAAGGA
F AGGGCTAAGATGAAGCCTGA
P3 909 1,045 R ACCACCTAAGAACCCATCCA
Pr TGCCCTTCACCACTGCTGGC
F GGGATGCAGGAGAACAGACA
P41,562 1,734 R GGCAGTTTGTGTTTGGTGGT
Pr TGCTCCCACTGCCTGGTGCT
F CAATCAAGGCCATGCCAGAA
P53,517 3,627 R CACATGGATCGGAGAGACAGA
Pr TGTGCCCACCGACCTCTCTGG
Inhibition of Histone Modifying Enzymes
Primary human derived macrophages were obtained as
previously described. The regulatory effect of HMTs on
transcription of S100A9 and S100A12was analyzed using specific
inhibitors. M1 macrophages which were cultured in the presence
of MCSF and IFN-γ under normal and high glucose conditions
were treated with inhibitors for SET7, SMYD3, and Mixed
Lineage Leukemia (MLL) histone methyltransferases (HMTs).
(R)-PFI-2 hydrochloride, a substrate-competitive inhibitor
which occupies the substrate peptide binding groove of SET7
(62) and EPZ031686 inhibitor for SMYD3 (63) were derived
from MedChem Express (US). WD Repeat Domain 5 (WDR5)
0103 inhibitor of MLL which disrupts WDR5 interaction
with MLL and inhibits MLL core complex methyltransferase
activity (64) was obtained from Bio-techne (US). The inhibitors
dissolved were in DMSO and corresponding concentrations of
DMSO were used as controls. Cells were treated at the indicated
concentrations from the time of isolation on up to 6 days
followed by RNA isolation.
Immunofluorescence Staining
Monocyte-derived macrophages were stimulated withMCSF and
INF-γ and cultured on cover slips (Neolab, germany) for 6 days
under normal and high glucose conditions. Cells were fixed using
2% paraformaldehyde (PFA) in PBS for 10min and washed with
0.5%TritonX-100 in PBS for 15min to permeabilize. Intracellular
structures were fixed with 4% PFA 10min again. Cells were
washed three times with PBS and stained for SET7/SET9 (Cell
Signaling, US). DRAQ5 (Life Technologies, Germany) was used
for nuclear staining. Expression and localization was analyzed
using the Leica TCS SP8 confocal laser scanning microscope.
Analysis of fluorescence intensity and the nucleus size in pixels
(regions of interest defined by DRAQ5 staining) were performed
using Fiji software (imagej.net).
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Statistics
All statistical calculation have been done with the statistical
software SAS, release 9.4 (SAS institute Inc., Cary, North
Carolina, USA). For qualitative factors, absolute, and relative
frequencies are given. Quantitative variables are presented by
their mean value and standard error. In order to compare the
mean values of two independent samples, a 2 sample t-test has
been used. For data not normally distributed Mann Whitney U-
test has been used instead. In order to compare more than two
samples, a one way ANOVA or a Kruskal-Wallis-Test has been
performed, as appropriate. In the case of a statistically significant
test result, post-hoc tests according to Scheffe or Dunn’s test have
been applied, respectively. For the comparison of themean values
of two paired samples (i.e., days 1 and day 6), a two paired t-test
has been used. In order to evaluate simultaneously the impact of
two factors on a quantitative outcome, a two way ANOVA has
been done. If necessary, an ANOVAwith repeated measurements
have been applied (i.e., for donors which have been measured
several times).
Correlation coefficients according to Spearman have been
used in order to quantify the degree of association. In general,
the result of a statistical test has been considered as significant
for p < 0.05 (∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 and
∗∗∗∗P < 0.0001).
RESULTS
Hyperglycemia Increases the Expression of
S100 Genes During Monocyte/Macrophage
Differentiation Under IFNγ Stimulation
We determined the expression of S100A9 and S100A12 at day 1
and day 6 of differentiation from monocytes into M1 resp. M2
macrophages. It is known that S100A8 and S100A9mRNA levels
decline during monocyte differentiation into macrophage (65).
Compared to macrophages, monocytes presented the greatest
mean expression levels of both S100A9 and S100A12 regardless
of glucose. Both genes declined duringmonocytes to macrophage
maturation and S100A12 was downregulated much stronger
than S100A9 (360-fold and 5.4-fold, respectively, for ns, NG
after 6 days) (Figure 1A). The effect of the stimulator on gene
expression was present from day 1 whereas glucose influenced
gene expression only from day 6 on. After 6 days, the highest
levels of S100A9 and S100A12were found inM1 compared toM0
and M2 macrophages (P < 0.0001 for both genes). In addition,
9 out of 10 donors showed increased S100A9 expression, up to
4.9-fold for individual donors, and 8 out of 10 donors showed
increased S100A12 expression, up to 3-fold for individual donors
after 6 days in M1 macrophages cultured under high glucose
conditions. We also analyzed protein levels of S100A9 and
S100A12 in monocytes and macrophages from healthy donors by
Western blot (Supplementary Figure 1). Similar as observed for
mRNA expression, we observed on protein level that S100A9 and
S100A12 proteins were more abundantly present in monocytes
compared to matured macrophages (not shown).
For the analysis of hyperglycemic memory in M1
macrophages, after 6 days, when the monocytes had
differentiated into macrophages, the medium was changed
from NG to NG, from HG to HG and from HG back to NG
(transient hyperglycemia, Figure 1B) while MCSF and IFNγ
was maintained. mRNA expression levels were analyzed after
12 days. Higher expression of S100A9 was observed in HG-HG
compared to NG-NG only (P = 0.0386 by paired t-test). The
increase was found in 5 out of 7 donors with highest increase
for individual donors being 2.8-fold (Figure 1B). When the
medium was reversed to normal glucose levels, expression of
S100A9 and S100A12 was increased in 4 of 7 donors compared to
macrophages that weremaintained in NGmedium. For S100A12,
higher expression was observed in HG-HG compared to NG-
NG conditions. Expression increased in 5 out of 7 analyzed
donors with highest levels for individual donors being 8.6-fold
(Figure 1B). When the medium was reversed to normal glucose,
higher S100A12 expression was observed compared to cells that
were in NG medium continuously. The increase was found in
6 out of 7 donors with highest levels of for individual donors
being 5.7-fold (Figure 1B). Thus, the observed differences at day
6 (Figure 1A) remain present at day 12.
Next, we investigated the effect of secondary pro-
inflammatory stimuli on glucose conditioned M0 macrophages
by measuring gene expression of S100A9 and S100A12
(Figure 1C). Monocytes were cultured in normal and high
glucose conditions and after 6 days these were challenged
overnight with TLR-ligands, Palmitic acid (PA) is a saturated
fatty acid with a role in atherogenesis and T2D (66). We
observed that LPS induced expression of both S100A9 and
S100A12 compared to non-stimulated controls and IFNγ
stimulated cells. This only reached significance for S100A12. We
observed that high glucose dramatically increased the expression
levels of S100A9 in response to PA (9.9-fold). Expression of
S100A12 was upregulated by glucose in LPS stimulated cells
(5.4-fold). Also other TLR-ligands/inflammatory stimulators
FSL1 and Pam3CK4 were used and IL-1β , IL-6, and IL-10 gene
expression was measured. It was found that IL-1β and IL-6
expression also increased under LPS in the HG cells. There was
no difference in expression between NG and HG cultured cells
when stimulated with FSL1 and Pam3CK4 (data not shown).
S100A9 and S100A12 Expression in
Monocytes of Diabetic Patients
We assessed whether S100A9 and S100A12 genes are
higher expressed and therefore relevant in monocytes from
prediabetic and diabetic patients (Supplementary Table 2).
Expression of S100A9 and S100A12 in diabetic patients
was not different compared to controls in our dataset
(Figures 2A,B). Interestingly, S100A9 and S100A12 expression
were tightly correlated in T1D, T2D and healthy controls (P
= < 0.0001 for all three) but not in prediabetic individuals
(Supplementary Table 3). Similarly, we observed in vitro
that the tight correlation between S100A9 and S100A12
was lost in M1 macrophages cultured in high glucose
conditions compared to NG (data not shown). FG or
HbA1c levels in prediabetic individuals were not as high
as seen in diabetic patients (Figure 2C). In prediabetics,
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FIGURE 1 | Hyperglycemia sustains the mRNA expression of S100 proteins during monocyte/macrophage differentiation. (A) RT-PCR analysis of mRNA expression
S100A9 and S100A12 in M0ns, M1IFNγ, and M2IL−4 macrophages cultured for 24 h or 6 days under normal (NG, 5mM) and high glucose (HG, 25mM) conditions,
n = 10. (B) M1 macrophages were generated in HG medium for 6 days, after which cultures were reverted to NG for another 6 days (transient HG). Controls were
maintained under, respectively, NG or HG the whole experiment, n = 7. (C) M0 macrophages cultured for 6 days in NG or HG conditions and stimulated for 16 h with
TLR-ligands. Data present mean ± SEM normalized to 18srRNA expression levels, n = 8. Statistical analysis was performed using two-way ANOVA with Scheffe’s test
(A) one-way (B) and Kruskal-Wallis with Dunn’s test (C).
monocytic inflammatory gene expression did not correlate
with fasting glucose levels (Figure 2B). Some individuals
with high expression had high fasting blood glucose levels
(Figure 2B). Also, we did not observe a correlation between
gene expression levels and HbA1c levels, BMI or weight (data
not shown).
Also, intracellular levels of S100A9 and S100A12 protein were
assessed in monocytes from diabetic patients with microvascular
complications (Supplementary Table 4). Monocytes are
classified into three subtypes based on CD14+ and CD16+
expression, which differ in function and phenotype (67).
By FACS (representative FACS plot for gating strategies;
Supplementary Figure 2), the frequencies of these monocyte
populations did not differ between controls and T2D patients
(Supplementary Figure 3). S100A9 and S100A12 expression
was determined in all CD14+ positive cells and within the
different subgroups according microvascular complications.
There was a trend for higher proportion (frequency) of S100
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FIGURE 2 | S100A9 and S100A12 expression in monocytes of diabetic patients. (A) RT-PCR analysis of S100A9 and S100A12 expression in PBMCs from
prediabetic individuals, diabetic patients and healthy controls normalized to CD14 expression. Data in bargraph present medians. Statistical differences between
groups was tested with Kruskal-Wallis-test. (B) Correlation between S100A9 and S100A12 expression and fasting glucose in pre-diabetic individuals. Number of XY
Pairs = 16. Graphs show 95% confidence band of best-fit line. Spearman’s correlation coefficient (r) and p-value are given in the graphs. (C) Fasting glucose and
HbA1c levels in prediabetic individuals, diabetic patients and healthy controls. Control (n = 21), Prediabetic (n = 19), T1D (n = 19), and T2D (n = 21). (One-way
ANOVA with Scheffé-post-hoc test). (D) S100A9 and S100A12 expression was analyzed by flow cytometry. Classical, intermediate and non-classical monocytes
subsets from T2D patients with microvascular complications (n = 11) compared to healthy controls (n = 4). Cells positive for HLA-DR were selected and all cells
expressing CD3, CD19, CD56 were excluded. Monocytes were gated based on CD14+ and CD16+ expression and frequencies of parent (HLA-DR population) are
plotted. Mann-Whitney-U-test. (E) S100A9 and S100A12 expression in T2D patients with Cardiovascular disease (CVD), nephropathy (N), or both, compared to
healthy controls. Statistical analysis by one-way ANOVA, data present mean +SEM.
positive cells in HLA-DR, lin- subset (cells positive for HLA-
DR with CD3, CD19, and CD56 positive cells excluded) for
S100A9 (35 ± 16 vs. 28 ± 11%) as well as for S100A12 (28
± 11 vs. 24 ± 12%) in T2D samples compared to healthy
controls (data not shown). Also, the MFI, the average intensity
of protein expression, of S100A9 in T2D was 1.5-fold higher
than healthy controls (86,485 ± 30,754 compared to 57,027 ±
44,782 units) as well as for S100A12, 1.7-fold increase compared
to healthy controls (244 ± 103 compared to 140 ± 69 units)
(Figure 2D). S100 protein expression in patients with CVD
compared to controls or patients with nephropathy, did not
differ in this dataset (Figure 2E). Further, no correlation of
S100A9, S100A12 protein expression was found with HbA1c and
other metabolic factors i.e., BMI, HDL or fasting glucose (data
not shown).
Local Chromatin Structure of S100A9 and
S00A12
Given the proximity of the two genes and their possible
co-regulation, we analyzed a publicly available dataset
on local chromatin structure by ChIP-seq from primary
human monocytes (68). We found enrichment of H3K27ac
and H3K4me3 on TSS <1kb of both genes. Additionally,
CTCF-ChIP-seq data showed marked enrichment in CTCF
sites 1kb upstream of S100A9 and 31kb downstream of
S100A12, overlapping with the second intron of S100A8.
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FIGURE 3 | Occupancy of H3k27ac and H3k4me3 from Macrophages (Mf) and Monocytes (Mo) From GSE109440 dataset. CTCF-ChIP-seq enrichment around
S100A9 and S100A12 genes. Data taken from Mo GSM1003508. Square highlights the enriched area of histone marks and CTCF In the S100A9 and S100A12
genomic locus. IGV Snapshot in the lower part is a zoom in of the area of interest.
Together, these data indicate an active transcription area
in S100A9 and S100A12 locus which correlates with the
expression of these genes. One smaller CTCF site was
found in between the two genes. More pronounced CTCF
boundaries were found to include S100A8 gene as well. In
the same study, differential H3K27Ace occupancy was found
in monocytes compared to macrophages at the promoter of
S100A12. This was not the case for S100A9, also pointing
toward independent transcriptional activity regulation
(Figure 3).
Hyperglycemia Contributes to Association
of Activating Histone Marks at S100A9 and
S100A12 Promoters
We investigated whether hyperglycemia affects the histone
codes on the promoters of S100A9 and S100A12 genes.
Using five individual donors, we analyzed the abundance of
epigenetic marks in five regions of S100 gene promoters in
M1 macrophages (Figure 4A). Hyperglycemia-induced effect
on the activating histone modifications H3K4me1, H3K4me3,
and AceH3 on promoters of both S100A9 and S100A12 was
similar (Figure 4B). H3K4me1 on the promoters of both
S100A9 and S100A12 genes had increased 1.3-fold for both
genes (P = 0.0.0160 and P = 0.0196, respectively), while
association of AceH3 had increased at both S100A9 and
S100A12 promoters (2.4 and 2.5-fold, respectively, P = 0.0129
and 0.0054 respectively, Figure 4B). The region with highest
level of H3K4me3 at the S100A9 promoter was at the
transcription start site (TSS) whereas general acetylation has
highest association at 1,200 and 1,600 bp upstream from the TSS
(Figure 4C).
We further examined whether these specific histone
modifications correlated with gene transcription. Gene
expression was increased under hyperglycemic conditions
in M1 macrophages in 4 out of 5 donors for both S100A9 and
S100A12 (Figure 5A). Donors 1 and 2 showed the highest level
of gene expression and increase in expression upon culture
in HG conditions (Figure 5A). However, the large change
in gene expression did not come along with pronounced
epigenetic changes (Figure 5B). Whereas, donor 3, 4, and
5 (to a lesser extent) which show only small increases in
gene expression, respond with large increases of H3K4me1,
H3K4me3, and AceH3 (Figure 5B). Therefore, fold change
increase in gene expression correlated negatively with increase
in level of histone modifications. On the other side, we observed
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FIGURE 4 | Histone code at promoter regions of S100A9 and S100A12. (A) DNA regions in the promoter of S100A9 and S100A12. (B) Level of histone modifications
in S100A9 and S100A12 promoter regions, average of 5 regions, Min to Max plot. Rabbit IgG was used as a negative control for the pull-down. Histone modifications
are presented as percent of input DNA and normalized to total H3 (by D2B12 antibody). Single comparisons between NG-HG made by students paired t-test, n = 5.
A 2 sample t-test has been used to compare mean values. (C) level of histone modifications in 5 different regions of the S100A9 and S100A12 promoter, mean +
SEM. ANOVA for repeated measurements have been performed for region (P1-P5) and glucose.
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FIGURE 5 | Changes in histones code correlate with gene transcription. (A) mRNA levels of S100A9 and S100A12 in M1 macrophages cultured for 6 under NG or
HG conditions. (B) Heatmap of histone modifications at S100A9 (top) and S100A12 (bottom) promoter of the 5 individual donors. (C) Total H3 levels (by D2B12
antibody). Comparisons made using a students paired t-test. Min to max, n = 5. (D) Linear regression analysis of change in gene expression with total H3, the
correlation coefficient was calculated by H3-mean and fold-change-values with n = 5.
that total H3, i.e., nucleosome density, was reduced under
hyperglycemic conditions in all donors (Figures 5B,C). Also,
stronger induction of gene expression (donor 1 and 2) by
HG then was associated with the least reduction in total
H3, hence a positive correlation of fold change in total H3
with fold change in gene expression (Figure 5D). Changes
in levels of H3 for the five individual primers e.g., specific
promoter regions, were also examined. For S100A9 P2 and
P4 region as well as P1 region within S100A12 promoter,
which is the nearest region to the transcription start site, an
almost linear correlation was observed between fold change
increases in H3 and fold change increase in gene expression
(Supplementary Figure 4).
Effect of Transient Hyperglycemia on the
Presence of Activating Histone Marks at
Promoters of S100A9 and S10012 Genes
Next, using four individual donors, we performed ChIP analysis
on M1 macrophages were after 6 days high glucose medium
reversed to normal glucose levels. Gene expression was increased
in M1 macrophages in 3 out of 4 donors for S100A9 and
all donors for S100A12 in both HG as well as transient
hyperglycemia compared to NG. Transient hyperglycemia still
presented 26 and 60% of the fold change increase induced by
HG for S100A9 and S100A12, respectively. By paired t-tests
significant only, H3K4me3 as well as AceH3 on the promoter
of both S100A9 and S100A12 were decreased in cell cultured
continuously under HG conditions, unlike previously shown
at day 6. H3K4me1 for S100A9 and H3K4me3 for S100A12
were sustained in transient hyperglycemia, significant by paired
t-test only. Presence of activating histone marks negatively
correlated with the increase in gene expression, similar to day
6 (data not shown). Changes in AceH3 and total H3 were
reversed in transient HG whereas changes in H3K4 mono
and trimethylation were similar between HG and transient
HG (Figure 6). Changes in H3 correlated positively with fold
change increases in gene expression for S100A9 in transient
hyperglycemia only (Supplementary Figure 5).
Inhibition of SET7 Affects Both S100A9 and
S100A12 Expression
Our next aim was to identify which histone modifying enzymes
mediated methylation in our cultured macrophages. The used
inhibitors did not affect the viability of cells at the concentrations
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FIGURE 6 | Modifications of histones at promoter regions in transient hyperglycemia. (A) M1 macrophages were generated in HG medium for 6 days, after which
cultures were reverted to NG for another 6 days (transient HG). Controls were maintained under, respectively, NG or HG the whole experiment. Level of histone
modifications at S100A9 (A) and S100A12 (B) promoter regions, average of 5 regions, Min to Max plot. Rabbit IgG was used as a negative control for the pull-down.
Histone modifications are presented as percent of input DNA and normalized to total H3. ANOVAs with repeated measurements have been performed to evaluate
differences between the three groups (HG, NG, Trans). Additional Scheffe post-hoc test for pairwise comparisons, n = 4.
used, tested by Alamar blue (data not shown). Epigenetic
modifying enzymes were inhibited in a dose-dependent fashion
and optimal working concentration was determined (data not
shown). By two-way ANOVA we determined how two factors
i.e., HMT inhibition and glucose influence S100A9 and S100A12
expression. Interaction between those terms was not significant.
In all three experiments expression levels of S100A9 and
S100A12 were affected by glucose (indicating that the donors
responded to hyperglycemia) as well as stimulatory factor
compared to non-stimulated cells and solvent controls). We
examined the relative contribution of methyltransferases on S100
gene upregulation by HG. Compared to the solvent control,
inhibition of SET7 led to an 3.8-fold decrease in both NG
and HG conditions for S100A9 and 11-fold in NG and 9.4-
fold decrease for S100A12 in HG (Figure 7A). Compared to the
solvent control, inhibition of SMYD3 downregulated expression
of S100A9 3.2-fold in NG and 1.1-fold in HG conditions,
compared to a 14-fold downregulation in NG and 3.4-fold
in HG conditions for S100A12 (Figure 7B). Therefore, cells
grown in HG were more resistant to the effects of HMTs
inhibitors. On the other side, inhibition ofMLL activity increased
S100A9 and S100A12 expression (Figure 7C). Compared to its
solvent control the increase was 1.2-fold in NG and 2.6-fold
in HG conditions for S100A9 compared to 1-fold in NG and
3.6-fold in HG conditions for S100A12 indicating that WDR5
inhibition tends to synergistically increase expression together
with glucose.
Glucose Affects SET7 Expression and
Localization in M1 Macrophages
Because our results showed that only H3K4me1 correlated
with gene transcription (P = 0.0093 and <0.0001 for S100A9
and S100A12, respectively, by linear regression analysis) and
SET7 inhibition downregulated S100 gene expression, we further
investigated SET7 during macrophage polarization and under
hyperglycemic conditions.We observed that SET7 expression did
not change in response to glucose or cytokines after 1 day of
macrophage polarization (Figure 8A, Supplementary Figure 6).
After maturation of monocytes to macrophages (day 6),
compared to M0 macrophages, SET7 expression had increased
in 4 out of 6 donors for M1 and all donors for M2 (P =
0.0007 for M1 and 0.0053 for M2 compared to M0) (Figure 8A,
Supplementary Figure 6). M1 macrophages stronger increased
expression of SET7 at days 6 compared to day 1, under HG
than in NG conditions (P = 0.0071 and 0.1203). For M2
macrophages this increase was only near significant and not
affected by culture in glucose (P = 0.0495 and 0.0452). Because
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FIGURE 7 | Regulation of S100A9 and S100A12 expression after inhibition of HMTs. RT-PCR analysis of the effect of treatment with PFI-2 hydrochloride inhibitor for
SET7 10µM concentrations corresponding dilutions of DMSO (A), EPZ031686 inhibitor for 20µM SMYD3 and corresponding to dilution of DMSO (B) or WDR5 0103
inhibition of MLL activity in 25µM concentration and corresponding vehicle control (C). Data present mean ± SEM normalized to 18S rRNA levels. Two-way ANOVA
have been performed including glucose (HG and NG) and stimulator (DMSO, PFI and ms) as two fixed factors. Further exploratory analyses for each gene and glucose
according to Scheffé.
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FIGURE 8 | SET7 expression and localization in primary human macrophages. (A) RT-PCR analysis of expression SET7 in M0 ns, M1 IFNγ and M2 IL−4 macrophages
cultured for 24 h or 6 days cultured under NG and HG conditions. Data present mean ± SEM normalized to 18SrRNA levels. Two-way ANOVA has been used for day
1 and 6 separately. Because of the interaction between day and stimulation, paired t-test has been used for comparison between the time-points (B,C)
Immunofluorescence/confocal imaging of SET7 protein expression in M1 macrophages cultured for 6 days cultured under NG and HG conditions. Quantification of
nuclear SET7 using fluorescene intensity/nucleus and intensity/area. Cells were fluorescent labeled with primary antibody against SET7 from Rabbit and secondary
antibodies were Cy3 donkey anti-rabbit (red) and DRAQ5 (blue) for nuclei. Scale bars from top to bottom equal 50, 10 and 10µm, n = 8.
SET7 translocates to the nucleus in endothelial cells in response
to high glucose (69) the localization of SET7 was investigated in
M0 and M1 macrophages by confocal microscopy in NG and
HG conditions. Both M0 and M1 type macrophages expressed
SET7 in their cytoplasm irrespective of glucose concentration
(data not shown). Quantification of nuclear SET7 showed that
the fluoresence intensity of the nuclei was was higher in M1
macophages compared to M0 macrophages (2.8-fold P = 0.0273
in NG, compared to 6.3-fold P = 0.0777 in HG) (Figure 8B).
The intensity/area in M1 in HG was higher compared to M1
macrophages in NG conditions 2.2-fold, P = 0.0472 meaning
that the fluorescent signal in the nucleus is stronger in glucose
cultured cells (Figure 8B). Hyperglycemic culture also caused
nuclear localization of SET7. A speckled intranuclear pattern
was observed (Figure 8C) that was absent in normoglycemically
cultured M1 macrophages.
DISCUSSION
Our hypothesis was that hyperglycemia induces metabolic
memory together with M1 skewing which is caused by
epigenetic switching. We focussed on S100A9 and S100A12
as we found the expression of these genes to be increased
by hyperglycemia during monocyte/macrophage differentiation
under IFNγ stimulation. For S100A12, the increase was
maintained up to 6 days after reversal to normoglycemia.
Hyperglycemic conditions indeed increased the association of
activating histone marks at S100A9 and S100A12 promoters
which correlated negatively with increase in gene expression but
positively with fold change in total H3. S100A9 and S100A12
gene expression might be regulated through SET7 and SMYD3
whereas SET7 expression and localization itself is affected by
glucose in M1 macrophages.
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S100A9 tend to be higher expressed in T2D and S100A12 in
T1D patients. In patient samples, also other in vivo factors affect
the outcome compared to the hypergycemic conditions in our
in vitro assays (e.g., fatty acids, TLR ligands). Another important
factor is the effect of the treatment the patients receive (70). FG
or HbA1c levels were not as high as seen in diabetic patients
and therefore might have affected the S100A9 and S100A12
expression in the prediabetic individuals. S100A9 and S100A12
expression were tightly correlated in monocytes from T1D, T2D,
and healthy controls but not in prediabetic individuals. Also
in lung diseases, the increased expression of S100A12 in acute
respiratory distress syndrome suggested that S100A12 is more
important in the onset of neutrophil influx compared to stages
of chronic inflammation. Indeed in sputum of cystic fibrosis and
chronic obstructive pulmonary disease patients, higher levels of
S100A8/A9 were observed (71). Therefore, the regulation and
ratio of the two different genes might provide more insight in the
mechanism of inflammation.
Hyperglycemia-induced changes of H3K4me1, H3K4me3,
and AceH3 was similar at promoters of S100A9 and S100A12
in M1 macrophages. As in RAW 264.7 macrophage-like cells
stimulated with LPS, it has been shown that high and ongoing
transcription was marked by either H3K79me2 or H3K36me3
and showed specific enrichment of motifs recognized by the NF-
κB and IRF proteins (72). A reason that we did not observe
strong association with transcription might be that H3K4me3
and transcriptional initiation are tightly linked but elongation
of RNApII afterwards might occur through methyltransferases
recognizing H3K36me3 (72, 73). AceH3 was highly increased by
glucose the interrogated overall S100A9 and S100A12 promoter
regions. In line with a more open chromatin state, less
nucleosomes were cross-linked to DNA, as reflected by total
H3 variants as recognized by our D2B12 antibody. Promotors
then might be more accessible to transcription factors that are
upregulated by IFNγ. For half of the donors, it was observed that
elements gaining AceH3 starting from lower levels, in concert
gain H3K4me1 whereas H3K4me3 remained relatively constant,
as reported before (22). Bone-marrow-derived macrophages
(BMDM) from T1D mice also show increased total HAT activity
and decreased HDAC activity relative to control macrophages
(74). In yeast, acetylation at specific residues that negatively
correlate with increased transcription was mostly seen at H4 (75).
Nucleosomes hamper TFs from binding the DNA and
therefore are general repressors of gene transcription (76).
Therefore, the positive effect of nucleosome density in our
study is not intuitive and indicates that the general rule of
activating and repressing marks is not valid in exceptional
cases or acts independently from each other. Similarly, in a
study where nucleosome density on a specific promoter was
manipulated by changing guanine-cytosine (GC) content, the
lowest GC% did not correlate to highest output i.e., promoter
activity (77). Nucleosomes are not bound 100% of the time
but assemble and disassemble in equilibrium and occupancy
varies genome wide. A reduction in nucleosome number
therefore can increase the variability of relative occupancy
since the histone pool is finite (78). Relative high occupancy
together with high DNA accessibility has been described
before (79). Nucleosome depletion also increased 15% but not
affected expression of 75% genes in yeast switched to glucose
medium. These could be genes that are already induced, or the
transcriptional activators and repressors may be dominant in
gene regulation (80). Activators of transcription are believed to
act by recruitment of chromatin remodellers (81) which promote
nucleosome removal (82). Chromatin remodeling complexes
such as SWItch/Sucrose Non-Fermentable (SWI/SNF) complex
accommodate single nucleosomes and their action is coupled
to Adenosine triphosphate (ATP) hydrolysis which biases the
spontaneous unwrapping of the DNA (77, 82, 83). One key
player in macrophages DNA wrapping is high mobility group
box1 (HMGB1). It resides in nucleus but is secreted after
LPS/IFNγ stimulus reducing histone content and activating
transcription (84). It was found to be sensitive to and activated
by exposure to high glucose (85). Most likely the combination
of different activating histone marks determines, together with
a decrease of bound H3, the activity of the S100A9 and S100A12
promotors, and histone content critical in interpreting chromatin
organization as it constitutes one layer of epigenetic regulation.
Hyperglycemia inhibited downregulation of S100 genes by
both SET7 and SMYD3 inhibition. The effect was always stronger
for S100A12 compared to S100A9 and cells grown in HG
conditions seemed more resistant to the inhibitory effects. On
the other side, WDR5, presenting the MLL complex activity,
tend to synergistically increase expression in the presence of
glucose. The key histone methyltransferase that is activated by
hyperglycemia is SET7/9 writing H3K4me1. SET7 is involved in
inflammatory signaling and found to be a co-activator of NF-κB
in THP-1 cells as well as in macrophages from diabetic mice (86).
SET7 expression was increased and H3K4me1 on NF-kB p65
promoter was associated with expression of NF-kB-dependent
oxidant/inflammatory genes COX2 and iNOS in PBMCs form
T2D patients (87). In our M0 and M2 macrophages, virtually
no expression of S100A9 or S100A12 was present, whereas
SET7 is expressed at a modest higher rate. Indicating that the
expression of S100 proteins associates with SET7 expression
only in M1 macrophages. Quantitative data indicated SET7
relocalisation to the nucleus. We cannot exclude that increased
methylation is a combined effect of several methyltransferases or
decreased activity of demethylases, which should be examined in
further studies.In this study we show that SMYD3 has effect on
specifically S100A12 promoter. SMYD3 however, despite existing
literature does not methylate H3K4 but far more efficiently
methylates H4K5 (88) and is mainly involved in regulation
of transcription and signal transduction pathways promoting
cancer development (89). SMYD3-mediated methylation of
MAP3K2 promoted the activation of the Ras/Raf/MEK/ERK
signaling module in cancer cell lines (90). Here, we show a
new role of SMYD3 in regulating S100 gene expression under
diabetic conditions.
Members of the MLL family show preferential methylation
levels and this is according to their localization in the chromatin
e.g., SET1A and B are found at promoter and preferential
trimethylate whereas MLL3 and 4 localize at enhancer regions
as is H3K4me1 (91). H3K4me1 at the promoter region is
even suggested to induce transcriptional silencing and restrict
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H3K4me3 reading, in macrophages among other cell types,
although it is not clear whether this is provoked by MLL3/4 or
the remaining methylation after demethylase activity (91, 92).
This could be an explanation for the negative correlation of
H3K4me1 with increased gene transcription. The authors also
observed that H3K4me1 for a group of acutely inducible genes,
was mediated by MLL3/4 and loss of this HMT even promoted
stimulus-dependent i.e., LPS induced gene expression without
changes in H3K4me3 levels (92).
After normalized glucose levels, memorable changes of S100
genes were found for S100A12. After 12 days the epigenetic
picture was different compared to 6 days. This could be either
effect of medium change or chronic exposure to HG, which
probably switches on a negative feedback mechanism that start
to inactivate chromatin by a decrease in activating marks on
the promoter of pro-inflammatory genes. H3K4me1 for S100A9
and H3K4me3 for S100A12 possibly mark metabolic memory.
Change in AceH3 as well as total H3 were reversible and therefore
seem more dynamic and responsive to metabolic changes. That
the changes on gene expression level are not as fast as changes in
epigenetic marks could be a consequence of stabilization of RNA.
LPS induced expression of S100A9, and even more of
S100A12, compared to non-stimulated controls. We observed
that high glucose dramatically increased the expression levels
of S100A9 in response to PA and of S100A12 in LPS
stimulated cells. Therefore, hyperglycemia augments stimulation
with TLR-ligands and S100 proteins are sensitive to glucose
conditioning. It has been shown before that high glucose induces
a priming effect in macrophages and sensitizes cells toward
inflammatory response (93, 94). It might be that due to the
fact that glucose directly elevates the expression of TLRs (95).
Another possible explanation would be that chromatin on S100
promoters is already opened and presence of secondary pro-
inflammatory mediators dramatically induce the expression of
these genes. Probably, both metabolic and epigenetic changes
contribute to observed effects in this study. Firstly, since
glucose metabolism determines immune cell activation and also
training of monocytes via the AKT–mTOR–HIF-1a pathway
(96) it had been hypothesized that high circulating levels of
glucose could program immune cells toward an inflammatory
phenotype through increased glucose utilization via glycolysis
(24). However, we observed that culture in high glucose
conditions did not change glucose uptake of M0 and M1
macrophages (data not shown), and it has been suggested
before that increased glucose supply, i.e., increased uptake
alone are not sufficient to drive inflammatory activation and
atherosclerosis in myeloid cells (94, 97, 98). Second, several
metabolic characteristics of M1 macrophages i.e., ROS, NO and
succinate, are important demethylase inhibitors and inhibiting
glycolysis or stimulating mitochondrial metabolism reduced
the formation of HDAC inhibitor lactate (99) which links
metabolism and AceH3 levels. Third, hyperglycemia-induced
ROS and methylglyoxal production has shown to regulate
expression of RAGE, S100A8, S100A12, and HMGB1 expression,
which was normalized by overexpression of mitochondrial
uncoupling protein 1, superoxide dismutase 2, or glyoxalase
I. Loss of GLO1 mimicked the effect of high glucose whereas
overexpression of GLO1 normalized the increased binding of
NFκB p65 and activator protein 1 to the respective promoters
(100), which might be mediated by SET7 (101). At last,
overexpression S100A8 and S100A9 led to increased IL-10,
whereas TN-α and IL-1β did not change (102). IL-10 mediates
many anti-inflammatory effects in macrophages, but also has
a role in metabolic programming; it inhibits glycolytic flux by
inhibiting translocation of GLUT1 to the membrane in LPS-
stimulated murine BMDMs (103).
Overall, an upregulation of S100 proteins by endogenous and
diabetes-relevant ligands in hyperglycemic conditions together
with memorable changes of S100 genes expression suggests that
they can be important players in diabetes-related inflammation.
Our results define an important role for epigenetic regulation
in macrophage mediated inflammation in diabetic conditions.
It remains to be studied if targeting epigenetic enzymes would
correlate with reduction of diabetes severity in vivo in preclinical
models. Individual differences in response to hyperglycemia and
pro-inflammatory stimuli suggest that S100 proteins can be used
to distinguish between responders and non-responders toward
hyperglycemia indicating risks in diabetes patients.
DATA AVAILABILITY STATEMENT
All relevant data is contained within the article. Raw data
supporting the conclusions of this article as well as relevant
materials such as protocols are available upon request to
interested researchers.
ETHICS STATEMENT
All studies were approved by the ethics and review committee
of Medical Faculty Heidelberg, University of Heidelberg (ethic-
vote-number S-383/2016; clinical trial number NCT03022721).
AUTHOR CONTRIBUTIONS
DM, KM, and JK contributed to the conception and design of
the study. KM and DM established the methods. DM performed
the research and analysis. JC and GD performed bioinformatic
analysis and interpretation. CW performed statistical analysis
of the data. VR, JK, MH, and MR contributed to the analysis
and interpretation of the results. DM wrote the first draft of
the manuscript. Preparation of patient samples and patient
details was done by SK. HK, VR, JC, JK, and MR contributed
to manuscript revision. All authors read and approved the
submitted version.
FUNDING
This project was funded by DFG GRK1874 (DIAMICOM).
ACKNOWLEDGMENTS
We acknowledge Christina Schmuttermaier for the technical
support on the monocyte isolations. PBMCs of diabetic patients
Frontiers in Immunology | www.frontiersin.org 16 June 2020 | Volume 11 | Article 1071
Mossel et al. Macrophage Epigenetic Programming by Hyperglycemia
were kindly provided by Dr. Thomas Fleming (Department
of Medicine I and Clinical Chemistry, Heidelberg-clinic). We
acknowledge financial support for the publication by the Baden-
Württemberg Ministry of Science, Research and the Arts and by
Ruprecht-Karls-Universität Heidelberg.
SUPPLEMENTARY MATERIAL




1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G,
et al. Global, regional, and national burden of cardiovascular diseases
for 10 causes, 1990 to 2015. J Am Coll Cardiol. (2017) 70:1–25.
doi: 10.1016/j.jacc.2017.04.052
2. The Emerging Risk Factors C. Diabetes mellitus, fasting blood glucose
concentration, and risk of vascular disease: a collaborative meta-
analysis of 102 prospective studies. Lancet. (2010) 375:2215–22.
doi: 10.1016/S0140-6736(10)60484-9
3. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat
Rev Immunol. (2011) 11:98. doi: 10.1038/nri2925
4. Garcia C, Feve B, Ferré P, Halimi S, Baizri H, Bordier L, et al. Diabetes
and inflammation: fundamental aspects and clinical implications. Diabetes
Metab. (2010) 36:327–38. doi: 10.1016/j.diabet.2010.07.001
5. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell
Metab. (2012) 15:432–7. doi: 10.1016/j.cmet.2011.11.013
6. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage
plasticity and polarization in tissue repair and remodeling. J Pathol. (2013)
229:176–85. doi: 10.1002/path.4133
7. Altmann C, Schmidt MHH. The role of microglia in diabetic retinopathy:
inflammation, microvasculature defects and neurodegeneration. Int J Mol
Sci. (2018) 19:110. doi: 10.3390/ijms19010110
8. Tesch GH. Macrophages and diabetic nephropathy. Semin Nephrol. (2010)
30:290–301. doi: 10.1016/j.semnephrol.2010.03.007
9. Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A.
Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic
strategies based on these targets. Int J Endocrinol. (2014) 2014:10.
doi: 10.1155/2014/674987
10. Boniakowski AE, Kimball AS, Jacobs BN, Kunkel SL, Gallagher KA.
Macrophage-mediated inflammation in normal and diabetic wound healing.
J Immunol. (2017) 199:17–24. doi: 10.4049/jimmunol.1700223
11. Tonna S, El-Osta A, Cooper ME, Tikellis C. Metabolic memory and diabetic
nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol.
(2010) 6:332–41. doi: 10.1038/nrneph.2010.55
12. Writing Team for the Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and Complications
Research Group. Effect of intensive therapy on the microvascular
complications of type 1 diabetes mellitus. JAMA. (2002) 287:2563–9.
doi: 10.1001/jama.287.19.2563
13. Hanefeld M, Temelkova-Kurktschiev T. Control of post-prandial
hyperglycemia–an essential part of good diabetes treatment and
prevention of cardiovascular complications. Nutr Metab Cardiovas Dis.
(2002) 12:98–107.
14. Hansen NW, Hansen AJ, Sams A. The endothelial border to health:
Mechanistic evidence of the hyperglycemic culprit of inflammatory disease
acceleration. IUBMB Life. (2017) 69:148–61. doi: 10.1002/iub.1610
15. Testa R, Bonfigli AR, Prattichizzo F, La Sala L, De Nigris V, Ceriello A. The
“metabolic memory” theory and the early treatment of hyperglycemia
in prevention of diabetic complications. Nutrients. (2017) 9:437.
doi: 10.3390/nu9050437
16. Keating ST, Plutzky J, El-Osta A. Epigenetic changes in
diabetes and cardiovascular risk. Circ Res. (2016) 118:1706–22.
doi: 10.1161/CIRCRESAHA.116.306819
17. Bannister AJ, Kouzarides T. Regulation of chromatin by histone
modifications. Cell Res. (2011) 21:381–95. doi: 10.1038/cr.2011.22
18. Davis FM, Schaller MA, Dendekker A, Joshi AD, Kimball AS, Evanoff
H, et al. Sepsis induces prolonged epigenetic modifications in bone
marrow and peripheral macrophages impairing inflammation and
wound healing. Arterioscler Thromb Vasc Biol. (2019) 39:2353–66.
doi: 10.1161/ATVBAHA.119.312754
19. Moores RC, Brilha S, Schutgens F, Elkington PT, Friedland JS.
Epigenetic regulation of matrix metalloproteinase-1 and−3 expression
in mycobacterium tuberculosis infection. Front Immunol. (2017) 8:602.
doi: 10.3389/fimmu.2017.00602
20. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of
inflammation by TLR-induced chromatin modifications. Nature. (2007)
447:972. doi: 10.1038/nature05836
21. Ifrim DC, Quintin J, Joosten LA, Jacobs C, Jansen T, Jacobs L, et al. Trained
immunity or tolerance: opposing functional programs induced in human
monocytes after engagement of various pattern recognition receptors. Clin
Vaccine Immunol. (2014) 21:534–45. doi: 10.1128/CVI.00688-13
22. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese
F, et al. Epigenetic programming of monocyte-to-macrophage
differentiation and trained innate immunity. Science. (2014) 345:1251086.
doi: 10.1126/science.1251086
23. El-Osta A. Glycemic memory. Curr Opin Lipidol. (2012) 23:24–9.
doi: 10.1097/MOL.0b013e32834f319d
24. van Diepen JA, Thiem K, Stienstra R, Riksen NP, Tack CJ, Netea
MG. Diabetes propels the risk for cardiovascular disease: sweet
monocytes becoming aggressive?. Cell Mol Life Sci. (2016) 73:4675–84.
doi: 10.1007/s00018-016-2316-9
25. Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, et al. Evaluating the
role of epigenetic histone modifications in the metabolic memory of type 1
diabetes. Diabetes. (2014) 63:1748–62. doi: 10.2337/db13-1251
26. Kuznetsova T, Prange KHM, Glass CK, deWintherMPJ. Transcriptional and
epigenetic regulation of macrophages in atherosclerosis. Nat. Rev. Cardiol.
(2020) 17:216–28. doi: 10.1038/s41569-019-0265-3
27. Khare SP, Habib F, Sharma R, Gadewal N, Gupta S, Galande S. HIstome—a
relational knowledgebase of human histone proteins and histone modifying
enzymes.Nucleic Acids Res. (2011) 40:D337–D342. doi: 10.1093/nar/gkr1125
28. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, et al.
Transient high glucose causes persistent epigenetic changes and altered gene
expression during subsequent normoglycemia. J Exp Med. (2008) 205:2409–
17. doi: 10.1084/jem.20081188
29. Kaikkonen MU, Spann NJ, Heinz S, Romanoski CE, Allison KA, Stender
JD, et al. Remodeling of the enhancer landscape during macrophage
activation is coupled to enhancer transcription. Mol Cell. (2013) 51:310–25.
doi: 10.1016/j.molcel.2013.07.010
30. Kittan NA, Allen RM, Dhaliwal A, Cavassani KA, Schaller M, Gallagher
KA, et al. Cytokine induced phenotypic and epigenetic signatures are key to
establishing specific macrophage phenotypes. PLoS ONE. (2013) 8:e78045.
doi: 10.1371/journal.pone.0078045
31. Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic
science to clinical application. Pharmacol Ther. (2016) 167:120–31.
doi: 10.1016/j.pharmthera.2016.07.015
32. Vogl T, Pröpper C, Hartmann M, Strey A, Strupat K, van den Bos
C, et al. S100A12 is expressed exclusively by granulocytes and acts
independently from MRP8 and MRP14. J Biol Chem. (1999) 274:25291–6.
doi: 10.1074/jbc.274.36.25291
33. Wang S, Song R,Wang Z, Jing Z,Wang S, Ma J. S100A8/A9 in inflammation.
Front Immunol. (2018) 9:1298. doi: 10.3389/fimmu.2018.01298
34. Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X. S100 proteins as an
important regulator of macrophage inflammation. Front Immunol. (2018)
8:1908. doi: 10.3389/fimmu.2017.01908
35. Schiopu A, Cotoi OS. S100A8 and S100A9: DAMPs at the crossroads
between innate immunity, traditional risk factors, and cardiovascular
disease.Mediators Inflamm. (2013) 2013:828354. doi: 10.1155/2013/828354
Frontiers in Immunology | www.frontiersin.org 17 June 2020 | Volume 11 | Article 1071
Mossel et al. Macrophage Epigenetic Programming by Hyperglycemia
36. Donato R. RAGE: a single receptor for several ligands and different cellular
responses: the case of certain S100 proteins. Curr Mol Med. (2007) 7:711–24.
doi: 10.2174/156652407783220688
37. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al.
RAGE mediates a novel proinflammatory axis: a central cell surface
receptor for S100/calgranulin polypeptides. Cell. (1999) 97:889–901.
doi: 10.1016/S0092-8674(00)80801-6
38. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, Van Zoelen MA,
et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor
4, promoting lethal, endotoxin-induced shock. Nat Med. (2007) 13:1042.
doi: 10.1038/nm1638
39. Okada K, Arai S, Itoh H, Adachi S, Hayashida M, Nakase H, et al. CD68
on rat macrophages binds tightly to S100A8 and S100A9 and helps to
regulate the cells’ immune functions. J Leukoc Biol. (2016) 100:1093–104.
doi: 10.1189/jlb.2A0415-170RRR
40. Alexaki VI, May AE, Fujii C, Ungern-Sternberg SNV, Mund C, et al. S100A9
induces monocyte/macrophage migration via EMMPRIN. Thromb Haemost.
(2017) 117:636–9. doi: 10.1160/TH16-06-0434
41. Greenlee KJ, Corry DB, Engler DA, Matsunami RK, Tessier P, Cook RG, et al.
Proteomic identification of in vivo substrates for matrix metalloproteinases 2
and 9 reveals a mechanism for resolution of inflammation. J Immunol. (2006)
177:7312–21. doi: 10.4049/jimmunol.177.10.7312
42. Isaksen B, Fagerhol M. Calprotectin inhibits matrix metalloproteinases by
sequestration of zinc.Mol Pathol. (2001) 54:289. doi: 10.1136/mp.54.5.289
43. Benedyk M, Sopalla C, Nacken W, Bode G, Melkonyan H, Banfi B, et al.
HaCaT keratinocytes overexpressing the S100 proteins S100A8 and S100A9
show increased NADPH oxidase and NF-κB activities. J Invest Dermatol.
(2007) 127:2001–11. doi: 10.1038/sj.jid.5700820
44. Markowitz J, Carson IIIWE. Review of S100A9 biology and its role in cancer.
Biochim Biophys Acta. (2013) 1835:100–9. doi: 10.1016/j.bbcan.2012.10.003
45. Korndörfer IP, Brueckner F, Skerra A. The crystal structure of the
human (S100A8/S100A9) 2 heterotetramer, calprotectin, illustrates how
conformational changes of interacting α-helices can determine specific
association of two EF-hand proteins. J Mol Biol. (2007) 370:887–98.
doi: 10.1016/j.jmb.2007.04.065
46. Vogl T, Stratis A, Wixler V, Völler T, Thurainayagam S, Jorch SK,
et al. Autoinhibitory regulation of S100A8/S100A9 alarmin activity
locally restricts sterile inflammation. J Clin Invest. (2018) 128:1852–66.
doi: 10.1172/JCI89867
47. Chernov AV, Dolkas J, Hoang K, Angert M, Srikrishna G, Vogl T,
et al. The calcium-binding proteins S100A8 and S100A9 initiate the early
inflammatory program in injured peripheral nerves. J Biol Chem. (2015)
290:11771–84. doi: 10.1074/jbc.M114.622316
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